Biogen

A shockwave hit the Alzheimer’s research community today after Biogen announced it was discontinuing two massive final phase human trials into the promising Alzheimer’s drug aducanumab. The announcement is the latest in a long line of failed Alzheimer’s drugs targeting the amyloid hypothesis.